GET DAILY SIGNALSPasithea Therapeutics Corp. (KTTA): Assessing the Path from $0.52 to the $3.00 Analyst Target
Key Takeaways
- The central target of $3.00 reflects the arithmetic mean of the verified analyst price targets reviewed; available data points to a single $3.00 target from H.C. Wainwright, which aggregators display as a $3.00 consensus.
- The latest verified price is roughly $0.52 (as of the November 11, 2026 close), implying a required upside of roughly 475% to reach $3.00.
- Coverage is extremely thin, and the target range is effectively a single figure ($3.00), so there is no meaningful high-to-low dispersion to weigh.
- The strongest supporting factor is the November 2026 FDA clearance of the investigational new drug (IND) application for PAS-004 in NF1-associated cNF, a condition with no approved systemic therapies.
- The biggest risks are a lack of revenue, an ongoing Nasdaq continued-listing deficiency, financing needs, and clinical-trial execution uncertainty typical of early-stage biotech.
- Readers can find more detail on the ticker's Major News, Today's Price Move, Forecast, and Earnings on dedicated pages.
- For automated market monitoring, explore Trending AI Robots.
Analyst Views on KTTA
Analyst coverage of KTTA remains limited, which calls for caution when weighing any consensus figure. The clearest attributable view comes from H.C. Wainwright, where analyst Sara Nik reiterated a $3.00 price target and Buy rating on August 17, 2026. Aggregators such as MarketBeat, TipRanks, MarketWatch, and Investing.com all show a $3.00 average, with the high and low estimates also listed at $3.00, highlighting the narrow spread among the few published opinions.
With every verifiable target at $3.00, the rounded central target stays at that level. This is not a broad Wall Street consensus but rather one firm’s perspective. The target sits well above the current share price, yet its limited foundation means it carries less weight than a typical multi-analyst average.
Current Market Position and Path Toward the Target
KTTA last closed near $0.52, inside a 52-week range of roughly $0.28 to $2.06. Reaching $3.00 would require a move of approximately 475% — a substantial gain by any measure. Such an advance would hinge on a decisive de-risking event that alters how the market values the pipeline rather than modest multiple expansion.
The shares rose about 44% in one session in early November 2026 after the company announced FDA clearance of its IND for PAS-004 in NF1-associated cNF, a condition affecting over 95% of people with NF1 and lacking an FDA-approved systemic therapy. That reaction underscores how binary and news-driven the stock remains: modest, high-conviction catalysts can shift it sharply in either direction.
Factors That Could Support a Move Toward the Target
- Regulatory momentum: IND clearance for PAS-004 opens the door to clinical development in an underserved indication, an important step for a pre-revenue biotech.
- Large unmet need: NF1-associated cNF has no approved systemic therapies, which could support a premium valuation if early data prove positive.
- Low valuation base: With a market capitalization near $17–19 million and book value per share above $1, the stock trades well below its net assets on paper, leaving room for re-rating on positive news.
- Analyst view: H.C. Wainwright’s Buy rating and $3.00 target reflect a view that the pipeline holds substantially more value than the current price implies.
Factors That Could Prevent the Target From Being Reached
- No revenue or approved products: KTTA is clinical-stage and generates losses, leaving it dependent on capital raises that can dilute shareholders.
- Listing risk: Nasdaq has flagged the company for failing to meet continued listing requirements, an overhang that can pressure the share price.
- Binary clinical risk: An adverse trial result or a clinical hold would likely invalidate the optimistic target quickly.
- Thin coverage and liquidity: A single analyst target on a micro-cap stock with modest float means price discovery is limited and volatility is high.
- Wide valuation gap: The 475% required move is so large that it depends on events that are years away, not near-term fundamentals.
Technical Levels and Market Structure
The 52-week range of roughly $0.28 to $2.06 provides the most relevant structural frame. The $2.06 high, set in late November 2025, sits below the $3.00 target and represents the nearest historical resistance if the stock re-rates. The $0.28 low marks a durable support zone, while the recent surge from near $0.35 to above $0.53 shows how quickly sentiment can shift on regulatory news. The stock remains a low-priced, high-volatility name where round-number and psychological levels matter less than discrete catalyst events. I also checked this using Tickeron’s AI Pattern Search Engine to see how the recent move compares with historical patterns in similar names.
Time Horizon and What Investors Should Monitor
Analyst price targets generally reflect a roughly 12-month research horizon, though no formal horizon is documented for this single target. Investors should watch the company’s next earnings report, estimated for late November 2026, along with updates on PAS-004 trial initiation, enrollment, and any financing announcements. Given the listing deficiency, progress toward regaining Nasdaq compliance is also critical. Changes to the lone analyst target, or the arrival of new coverage, would be informative.
Exploring AI Daily Buy/Sell Signals
For traders navigating volatile micro-cap names, AI Daily Buy/Sell Signals offer a data-driven complement to fundamental research. The system uses artificial intelligence to continuously monitor thousands of stocks and ETFs, generating Buy, Sell, or Hold signals based on changing market conditions, technical behavior, and AI-driven analysis. This can help traders discover new opportunities, monitor existing positions, and spot shifting trends more efficiently than manual screening. Consider reviewing these signals as part of a broader, diversified research process.
Final Assessment
Can KTTA reach $3.00? The target is real but rests on a very thin base — essentially one analyst’s view — and requires a roughly 475% gain from the current price. The bull case hinges on PAS-004’s IND clearance translating into successful clinical development in an indication with high unmet need, while the bear case emphasizes a pre-revenue business model, Nasdaq listing concerns, dilution risk, and the binary nature of early-stage biotech. The wide gap between price and target reflects genuine uncertainty, not a near-term expectation. Investors should treat $3.00 as a high-conviction, catalyst-dependent scenario and monitor clinical milestones, financing, and listing status before drawing conclusions.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
KTTA in upward trend: price rose above 50-day moving average on November 03, 2026
KTTA moved above its 50-day moving average on November 03, 2026 date and that indicates a change from a downward trend to an upward trend. In 40 of 46 similar past instances, the stock price increased further within the following month. The odds of a continued upward trend are 87%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on November 03, 2026. You may want to consider a long position or call options on KTTA as a result. In 74 of 93 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 80%.
The Moving Average Convergence Divergence (MACD) for KTTA just turned positive on November 03, 2026. Looking at past instances where KTTA's MACD turned positive, the stock continued to rise in 34 of 45 cases over the following month. The odds of a continued upward trend are 76%.
The 10-day moving average for KTTA crossed bullishly above the 50-day moving average on November 11, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 14 of 17 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 82%.
Following a +3.68% 3-day Advance, the price is estimated to grow further. Considering data from situations where KTTA advanced for three days, in 141 of 194 cases, the price rose further within the following month. The odds of a continued upward trend are 73%.
Bearish Trend Analysis
The 10-day RSI Indicator for KTTA moved out of overbought territory on November 09, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 17 similar instances where the indicator moved out of overbought territory. In 16 of the 17 cases, the stock moved lower in the following days. This puts the odds of a move lower at 90%.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 4 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where KTTA declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
KTTA broke above its upper Bollinger Band on November 03, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for KTTA entered a downward trend on November 02, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 46 (best 1 - 100 worst), indicating steady price growth. KTTA’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.388) is normal, around the industry mean (3.498). P/E Ratio (-0.429) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (440.869).
The Tickeron PE Growth Rating for this company is 75 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. KTTA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry Biotechnology
Advertisement